This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): MK-8742/MK-5172
Merck is developing a fixed dose combination of MK-8742 (elbasvir), a HCV nonstructural protein NS5a inhibitor, and MK-5172 (grazoprevir), a second generation HCV NS3/4A protease inhibitor.
Additional information available to subscribers only: